Figure 6.
Pretreatment with reslizumab did not reduce the number or severity of post-treatment adverse events (AE). The number of AEs reported in each group during the first 10 days post-treatment is shown in A. B shows the severity of these post-treatment reactions in individual subjects who received reslizumab (subjects 1–4) or placebo (subjects 5–8). Abbreviation: DEC, diethylcarbamazine citrate.